CLINICAL TRIAL SUMMARY

MDACC Study No:2012-0602 (clinicaltrials.gov NCT No: NCT01897012)
Title:A Phase 1 Trial of MLN8237 Plus Romidepsin for Relapsed/Refractory Aggressive B-cell and T-cell Lymphomas
Principal Investigator:Michelle A. Fanale
Treatment Agent:MLN8237; Romidepsin
Study Status:Open
Study Description:The goal of this clinical research study is find the highest tolerable dose
combination of romidepsin and MLN8237 that can be given to patients with
relapsed/refractory aggressive B- or T-cell lymphoma including: Hodgkin
lymphoma, Burkitt lymphoma (BL), double-hit lymphoma (DHL), another type of
c-MYC positive B-cell lymphoma, diffuse large B cell lymphoma (DLBCL), mantle
cell lymphoma (MCL), or T-cell lymphoma (TCL).

Romidepsin is designed to stop the growth of cancer cells and block new blood
vessels from forming around the cancer cells. This may cause the cancer cells
to die.

MLN8237 is designed to block a protein that is needed for cell division and
cancer growth. By blocking this protein, the drug could cause cancer cells to
die.

Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase I
Treatment Agents:MLN8237
Romidepsin
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:NCI/CTEP
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Michelle A. Fanale
Dept:Lymphoma
For Clinical Trial Enrollment:713-792-2806
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults